Dialog Box

New targeted therapy for patients with cholangiocarcinoma available in Australia

Cholangiocarcinoma (CCA) is a rare cancer that forms in the bile ducts, either inside or outside the liver (intrahepatic and extrahepatic). 

Intrahepatic cholangiocarcinoma particularly can harbour genetic alterations in fibroblast growth factor receptor 2 (FGFR2), which can be molecularly targeted by several clinically active kinase inhibitors; one of which is pemigatinib (trade name: PEMZYRE).

The phase 2 FIGHT-202 study has evaluated the safety and anti-tumour activity of pemigatinib in patients with advanced or metastatic cholangiocarcinoma with FGFR2 alterations. Results of this trial included a 35% response rate, and have been published in the Lancet Oncology. This study has led to the approval of pemigatinib by regulatory agents including the FDA and EMA, and is currently under TGA evaluation.

Specialised Therapeutics have made early access to this drug available to eligible patients in Australia via a Co-Pay Access Program. Please contact Specialised Therapeutics for further information.

Full study

Learn more about this study here.

Learn More

16 May 2022
Category: News